Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-08-14
Tempus AI, Inc.
Tempus sells oncology-focused genomic diagnostics, clinical workflow software, and data and AI tools to providers and biopharma customers.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Diagnostics Feeding an Oncology Intelligence Loop
The upside case is a disciplined mix-shift story, not a pure AI narrative. If test volume, reimbursement, MRD, and data products scale together while financing risk fades, equity compounding can track the bullish end of consensus.

Analysis

Thesis
Tempus can outgrow normal diagnostics peers by turning rising oncology test volume, reimbursement uplift, and MRD expansion into a higher-margin data and workflow engine; if bookings convert and cash flow turns sustainably positive, the market can keep valuing it as an oncology intelligence platform rather than just a premium lab.
Last Economy Alignment
AI makes Tempus’ multimodal data, embedded workflows, and compliance layer more valuable, while its diagnostics substrate limits pure software commoditization; reimbursement still gates value capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
The upside is a business-mix upgrade, not a software fantasy. Core diagnostics should keep compounding on oncology volume, MRD broadens the care continuum, and reimbursement gains lift average selling prices. If Data and Applications converts bookings into recognized revenue and Tempus proves it can self-fund growth, investors can keep assigning a healthy platform multiple even with some compression from today.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is not technology failure; it is monetization failure. Tempus must prove that reimbursement gains, MRD scale, and Data and Applications conversion can shift gross profit mix fast enough to justify platform-style valuation support. If it stays mostly a premium lab, the AI layer will help operations but not equity compounding. The near-term gates are Q4 2026 cash-flow positivity and a clean Personalis close.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.64
They sit inside cancer testing and care workflows, so every test can create data that makes their software and research products better. The risk is that payers and regulators still control much of the economics, so they must become a trusted action layer, not just a smart lab.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$62.64
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case